Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding moieties

Biomacromolecules

Volumn 8, Issue 7, 2007, Pages 2237-2243

  Murphy, Matthew B ^a   Hartgerink, Jeffrey D ^a,b   Goepferich, Achim ^c   Mikos, Antonios G ^a  

^a Rice University   (United States)

^b RICE UNIVERSITY   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DELIVERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYAPATITE; MASS SPECTROMETRY; MOLECULAR MASS; SYNTHESIS (CHEMICAL); TISSUE ENGINEERING;

BISPHOSPHONATE PAMIDRONATE; BONE-BINDING PROPERTIES; PEPTIDE-HYDROXYAPATITE BINDING; POLYASPARTIC ACID; POLYGLUTAMIC ACID;

PEPTIDES;

ASPARTIC ACID; GLUTAMIC ACID; HYDROXYAPATITE; PAMIDRONIC ACID; PHOSPHATE BUFFERED SALINE;

ADSORPTION; ARTICLE; BINDING AFFINITY; CALCIUM BINDING; CHEMICAL MODIFICATION; CONJUGATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PARTICLE SIZE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

CALCIUM; DIPHOSPHONATES; DURAPATITE; PEPTIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE ENGINEERING;

EID: 34547095490     PISSN: 15257797     EISSN: None     Source Type: Journal    
DOI: 10.1021/bm070121s     Document Type: Article

References (24)

1. Mistry, A. S.; Mikos, A. G. Tissue engineering strategies for bone regeneration. Adv. Biochem. Eng. Biotechnol. 2005, 94, 1-22.
2. Fu, K.; Klibanov, A. M.; Langer, R. Protein stability in controlled-release systems. Nat. Biotechnol. 2000, 18, 24-25.
3. Hirabayashi, H.; Fujisaki, J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin. Pharmacokinet. 2003, 42, 1319-1330.
4. Devogelaer, J. P. Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr. Opin. Rheumatol. 2000, 12, 331-335.
5. Fisher, J. E.; Rogers, M. J.; Halasy, J. M.; Luckman, S. P.; Hughes, D. E.; Masarachia, P. J.; Wesolowski, G.; Russell, R. G. G.; Rodan, G. A.; Reszka, A. A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 133-138.
6. Astrand, J.; Aspenberg, P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskeletal Disord. 2002, 3, 1-5.
7. Giuliani, N.; Pedrazzoni, M.; Negri, G.; Passeri, G.; Impicciatore, M.; Giras.le, G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice. Bone 1998, 22, 455-461.
8. Reinholz, G. G.; Getz, B.; Pederson, L.; Sanders, E. S.; Subramaniam, M.; Ingle, J. N.; Spelsberg, T. C. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000, 60, 6001-6007.
9. Still, K.; Phipps, R. J.; Scutt, A. Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro, Calcif. Tissue Int. 2003, 72, 143-150.
10. Uludag, H.; Gao, T.; Wohl, G. R.; Kantoci, D.; Zernicke, R. F. Bone affinity of a bisphosphonate-conjugated protein in vivo. Biotechnol. Prog. 2000, 16, 1115-1118.
11. Fernandez, D.; Vega, D.; Goeta, A. Alendronate zwitterions bind to calcium cations arranged in columns. Acta. Crystallogr. 2003, C59, m543-545.
12. Merck. Fosamax Product Information Sheet. Merck and Company, Inc. Whitehouse Station, NJ 08889; available online at www.merck.com.
13. Lin, J. H. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996, 18, 75-85.
14. Rutkowski, J. L.; Johnson, D. A.; Smith, D. M. Clinical concerns of alendronate use. J. Oral Maxillofac. Surg. 2007, 65, 363-364.
15. Yokogawa, K.; Miya, K.; Sekido, T.; Higashi, Y.; Nomura, M.; Fujisawa, R.; Morito, K.; Masamune, Y.; Waki, Y.; Kasugai, S.; Miyamoto, K. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 2001, 142, 1228-1233.
16. Kasugai, S.; Fujisawa, R.; Waki, Y.; Miyamoto, K.; Ohya, K. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J. Bone Miner. Res. 2000, 15, 936-943.
17. Wang, D.; Miller, S.; Sima, M.; Kopeckova, P.; Kopecek, J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjugate Chem. 2003, 5, 853-859.
18. Gittens, S. A.; Bansal, G.; Kucharski, C.; Borden, M.; Uludag, H. Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes. Mol. Pharmaceutics 2005, 2, 392-406.
19. Boskey, A. L.; Posner, A. S. Conversion of amorphous calcium phosphate to microcrystalline hydroxyapatite. A pH-dependent, solution-mediated, solid-solid conversion. J. Phys. Chem. 1973, 77, 2313-2317.
20. Landi, E.; Tampieri, A.; Celotti, G.; Sprio, S. Densification behaviour and mechanisms of synthetic hydroxyapatites. J. Eur. Ceram. Soc. 2000, 20, 2377-2387.
21. Uludag, H.; Kousinioris, N.; Gao, T.; Kantoci, D. Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol. Prog. 2000, 16, 258-267.
22. Sarig, S. Aspartic acid nucleates the apatite crystallites of bone: a hypothesis. Bone 2004, 35, 108-113.
23. Lin, J. H.; Chen, I. W.; DeLuna, F. A. On the absorption of alendronate in rats. J. Pharm. Sci. 1994, 83, 1741-1746.
24. Ogawa, K.; Mukai, T.; Arano, Y.; Ono, M.; Hanaoka, H.; Ishino, S.; Hashimoto, K.; Nishimura, H.; Saji, H. Development of a Rhenium-186-Labeled MAG3-Conjugated Bisphosphonate for the Palliation of Metastatic Bone Pain Based on the Concept of Bifunctional Radiopharmaceuticals. Bioconjugate Chem. 2005, 16, 751-757.